News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘TargetedTherapy’ clear

  • A new technology developed at Dana-Farber may make it possible to target "undruggable" proteins and overcome drug resistance by using a cancer cell's own protein-degrading machinery to destroy, not just inhibit, cancer proteins.

Tags: BasicResearch, TargetedTherapy

  • Patients whose metastatic stomach or esophageal cancers were driven by a mutated HER2 gene had markedly improved response rates and survival when bevacizumab (Avastin) was added to a standard drug combination according to a new study led by scientists at Dana-Farber Cancer Institute,

Tags: TargetedTherapy

  • A new oral drug caused dramatic shrinkage of a patient's rare, aggressive form of soft-tissue cancer that was driven by an abnormally activated protein, physician-scientists from Dana-Farber Cancer Institute report.

Tags: Sarcoma, TargetedTherapy

  • A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber who led the worldwide clinical trial.

Tags: KinaseInhibitor, Sarcoma, TargetedTherapy

  • The Cancer Genome Atlas Research Network has identified a large number and variety of DNA alterations in squamous cell lung cancer tumors, which could serve as potential therapeutic targets for treating the second most common type of lung cancer.

Tags: Genomics, LungCancer, TargetedTherapy

  • Results from a study evaluating an oral daily dose of the drug enobosarm, shows promise for women with metastatic, androgen receptor positive, estrogen receptor positive breast cancer.

Tags: BreastCancer, TargetedTherapy

  • A targeted drug that reduces blood flow to tumors prolonged the survival of patients with advanced stomach cancer after standard treatments failed, according to results of large multicenter clinical trial led by scientists at Dana-Farber Cancer Institute.

Tags: chemotherapy, TargetedTherapy

  • Regorafenib was found to reduce the risk of disease progression or death by more than 70 percent in patients whose tumors had become resistant to Gleevec and Sutent.

Tags: DrugResistance, Sarcoma, TargetedTherapy

  • Dana-Farber researchers report in the New England Journal of Medicine that ibrutinib, a newly approved drug for Waldenström's Macroglobulinemia, continues to control the rare blood cancer, with 95 percent of patients surviving for two years.

Tags: TargetedTherapy, TranslationalResearch, Lymphoma

  • Newly discovered gene mutations in certain non-small cell and colorectal cancers share similarities with other genetic abnormalities that are known to respond to targeted cancer treatments. This suggests that existing therapies, already approved, could be used to treat patients with these tumors.

Tags: ColonCancer, Genomics, KinaseInhibitor, LungCancer, TargetedTherapy

Showing 21-30 of 48 items